{"created":"2023-06-19T10:44:07.103029+00:00","id":4505,"links":{},"metadata":{"_buckets":{"deposit":"3efe39de-b048-4b53-a72a-d3dff1633a61"},"_deposit":{"created_by":11,"id":"4505","owners":[11],"pid":{"revision_id":0,"type":"depid","value":"4505"},"status":"published"},"_oai":{"id":"oai:shiga-med.repo.nii.ac.jp:00004505","sets":["30:62:231"]},"author_link":["2107","8788","184"],"item_4_biblio_info_6":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2023-05-22","bibliographicIssueDateType":"Issued"},"bibliographic_titles":[{},{"bibliographic_title":"Brain Tumor Pathology","bibliographic_titleLang":"en"}]}]},"item_4_creator_3":{"attribute_name":"著者別名","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"中洲, 敏"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"中洲, 庸子"}],"nameIdentifiers":[{},{}]}]},"item_4_description_4":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"The WHO 2021 classification defines IDH wild type (IDHw) histologically lower-grade glioma (hLGG) as molecular glioblastoma (mGBM) if TERT promoter mutation (pTERTm), EGFR amplification or chromosome seven gain and ten loss aberrations are indicated. We systematically reviewed articles of IDHw hLGGs studies (49 studies, N = 3748) and meta-analyzed mGBM prevalence and overall survival (OS) according to the PRISMA statement. mGBM rates in IDHw hLGG were significantly lower in Asian regions (43.7%, 95% confidence interval [CI: 35.8-52.0]) when compared to non-Asian regions (65.0%, [CI: 52.9-75.4]) (P = 0.005) and were significantly lower in fresh-frozen specimen when compared to formalin-fixed paraffin-embedded samples (P = 0.015). IDHw hLGGs without pTERTm rarely expressed other molecular markers in Asian studies when compared to non-Asian studies. Patients with mGBM had significantly longer OS times when compared to histological GBM (hGBM) (pooled hazard ratio (pHR) 0.824, [CI: 0.694-0.98], P = 0.03)). In patients with mGBM, histological grade was a significant prognostic factor (pHR 1.633, [CI: 1.09-2.447], P = 0.018), as was age (P = 0.001) and surgical extent (P = 0.018). Although bias risk across studies was moderate, mGBM with grade II histology showed better OS rates when compared to hGBM. ","subitem_description_type":"Abstract"}]},"item_4_description_42":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"subitem_description":"Journal Article","subitem_description_type":"Other"}]},"item_4_publisher_32":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"Springer Nature"}]},"item_4_relation_10":{"attribute_name":"PubMed番号","attribute_value_mlt":[{"subitem_relation_type_id":{"subitem_relation_type_id_text":"37212969","subitem_relation_type_select":"PMID"}}]},"item_4_relation_11":{"attribute_name":"DOI","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"10.1007/s10014-023-00463-8"}],"subitem_relation_type_id":{"subitem_relation_type_id_text":"https://doi.org/10.1007/s10014-023-00463-8","subitem_relation_type_select":"DOI"}}]},"item_4_rights_12":{"attribute_name":"権利","attribute_value_mlt":[{"subitem_rights":"© 2023. The Author(s), under exclusive licence to The Japan Society of Brain Tumor Pathology. "}]},"item_4_source_id_7":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1433-7398","subitem_source_identifier_type":"ISSN"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"NAKASU, Satoshi"}],"nameIdentifiers":[{},{},{}]},{"creatorNames":[{"creatorName":"DEGUCHI, Shoichi"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"NAKASU, Yoko"}],"nameIdentifiers":[{},{}]}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"IDH wild type","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Lower-grade glioma","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"TERT promoter mutation","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"Molecular glioblastoma","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"eng"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"journal article","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis"}]},"item_type_id":"4","owner":"11","path":["231"],"pubdate":{"attribute_name":"公開日","attribute_value":"2023-06-06"},"publish_date":"2023-06-06","publish_status":"0","recid":"4505","relation_version_is_last":true,"title":["IDH wild-type lower-grade gliomas with glioblastoma molecular features: a systematic review and meta-analysis"],"weko_creator_id":"11","weko_shared_id":-1},"updated":"2023-06-19T11:06:10.341332+00:00"}